Loratadine

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Loratadine

Examples of brand names: Clarityn [DE]

ATC code: R06AX13

Main use (for orientation): Allergies

Documented research summary

THCV-induced TRPV2 calcium influx was inhibited by loratadine in cells (35714693). A preclinical receptor finding, not a clinical loratadine–cannabinoid drug–drug interaction. CYP susceptibility supports a hypothesis for CBD assessment, not a measured combination.

Uncertainties and limitations

Documented individual title/abstract review with selected relevant full texts; not an exhaustive worldwide systematic review and no independent human professional approval. Missing data do not establish safety. All 28 cannabinoids define the search scope, not 28 clinically studied pairs per active substance.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

THCV – laboratory and animal studies

Finding ID: B0461

Type of result: Context-specific finding

Observation: In the cell model, the THCV-mediated TRPV2 response was reduced.

Mechanism: Loratadine inhibits THCV-induced TRPV2 currents and calcium influx.

Study type: Cell experiments, receptor pharmacodynamics

Context studied: HEK293 cells with human/murine TRPV2 and endometrial cells.

Clinical interpretation: Applicability to humans is unresolved; preclinical endpoint, not clinical evidence of treatment efficacy or safety.

Limitations and uncertainties: No clinical antihistamine–THCV study; do not transfer a concentration/receptor finding to a treatment effect.

Original sources for this finding: Loratadine, an antihistaminic drug, suppresses the proliferation of endometrial stromal cells by inhibition of TRPV2. [VF_P_35714693]

References and access status

[VF_L_D0345] Loratadine 10 mg Tablets - Summary of Product Characteristics (SmPC) - (emc) | 8911

Original source / bibliographic reference

Authors: Marketing authorisation holder; product information via emc

Year: 2023

Source type: Official medicine information; relevant identity, PK, PD and DDI sections read individually

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[VF_P_35714693] Loratadine, an antihistaminic drug, suppresses the proliferation of endometrial stromal cells by inhibition of TRPV2.

Original source / bibliographic reference

Authors: Van den Eynde C, Held K, Ciprietti M, De Clercq K, Kerselaers S, Marchand A, Chaltin P, Voets T, Vriens J.

Year: 2022

Source type: Scientific publication; precise study type and suitability described in the finding or individual review

DOI: 10.1016/j.ejphar.2022.175086

PMID: 35714693

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility